Generic entry timeline

SAXAGLIPTIN HYDROCHLORIDE generics — when can they launch?

SAXAGLIPTIN HYDROCHLORIDE (SAXAGLIPTIN HYDROCHLORIDE) · · 2 active US patents · 0 expired

Earliest patent expiry
2028-11-30
3 years remaining
Full patent estate to
2028-11-30
complete protection through 2028
FDA approval
2009

Where SAXAGLIPTIN HYDROCHLORIDE sits in the generic timeline

Imminent generic cliff: earliest active US patent for SAXAGLIPTIN HYDROCHLORIDE expires in 2028 (~3 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Formulation — 2 patents

Sample patent estate

Showing 2 of 2 active US patents. View full estate on the SAXAGLIPTIN HYDROCHLORIDE drug page →

  • US7951400 Formulation · expires 2028-11-30
    This patent protects a coated tablet formulation that includes saxagliptin hydrochloride, a DPP4-inhibitor, and various conventional excipients.
    USPTO title: Coated tablet formulation and method
  • US7951400 Formulation · expires 2028-11-30
    This patent protects a coated tablet formulation that includes saxagliptin hydrochloride, a DPP4-inhibitor, and various conventional excipients.
    USPTO title: Coated tablet formulation and method

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on SAXAGLIPTIN HYDROCHLORIDE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →